期刊文献+

他克莫司缓解大鼠自体移植静脉桥内膜增生的研究

Effect of tacrolimus on intimal hyperplasia in autogenous vein grafts of rats
下载PDF
导出
摘要 目的探讨他克莫司对大鼠自体移植静脉移植物(静脉桥)内膜增生的影响。方法 (1)选取28只雄性SD大鼠,建立颈外静脉移植颈总动脉模型,将大鼠随机分为实验组和对照组。实验组大鼠肌注他克莫司0.2 mg/(kg·d),对照组大鼠肌注相同剂量生理盐水。术后2周、4周采集大鼠移植静脉桥,采用HE染色法检测大鼠新生内膜厚度;采用免疫印迹法检测细胞周期蛋白依赖性激酶抑制剂p27表达水平,比较两组大鼠静脉桥组织中p27蛋白表达情况。(2)将人大隐静脉平滑肌细胞分为实验组(根据他克莫司浓度分4个亚组进行干预)和对照组(PBS缓冲液干预)。采用MTT法检测比较各组细胞增殖情况;采用Transwell小室法观察比较各组细胞迁移情况。结果 (1)与对照组比较,术后2周,实验组大鼠移植静脉桥新生内膜厚度明显减少(P<0.05),术后4周时减少更为明显(P<0.01)。经他克莫司治疗后2周和4周实验组大鼠移植静脉桥组织中p27蛋白水平显著高于对照组,差异均有统计学意义(P<0.05或0.01)。(2)不同浓度的他克莫司对HSVSMC增殖均产生抑制作用,随着其浓度增高抑制作用增强,有明显剂量效应关系;半抑制浓度(IC50)为390 nmol·L-1。他克莫司对HSVSMC迁移有明显的抑制作用,他克莫司浓度越高抑制作用越显著,浓度达到2 000 nmol·L-1时,抑制率最高,几乎无细胞迁移。结论他克莫司对自体静脉移植术后静脉桥再狭窄具有明显抑制作用,其机制可能与p27蛋白表达上调,抑制静脉平滑肌细胞增殖与迁移有关。 Objective To study the effects of tacrolimus on intimal hyperplasia in autogenous vein grafts of rats.Methods( 1) After jugular vein-to-artery bypass grafting surgery,28 male SD rats were randomly divided into the treatment group and control group,treatment group received intramuscular injections of tacrolimus 0. 2 mg /( kg·d),while the control group received saline. The vein grafts were harvested after 2 or 4 weeks of operation. HE staining was performed for histological changes of grafted vein intimal membranes; the expression level of cyclin-dependent kinase inhibitor p27 in the vein grafts was detected by western blot,the expression level of p27 was compared between two groups.( 2) Human saphenous vein smooth muscle cells were treated with tacrolimus( treatment group,including four subgroups depends on the concentration gradient of tacrolimus) or PBS( control group).Cell proliferation was assayed by MTT and migration was observed by Transwell chamber. Results( 1) After 2 and 4weeks of intervention,intimal thickness in treatment group was decreased significantly in treatment group compared to control group( P 〈 0. 05),and the decrease was more significant after 4 weeks of intervention( P 〈 0. 01). The expression level of p27 in the treatment group was significantly higher than that in control group in treatment group( P 〈 0. 05 or 0. 01).( 2) Difference concentration of tacrolimus can inhibit cell proliferation,and had the dose-dependent effect on inhibiting the cell proliferation( P 〈 0. 01). 50% inhibiting concentration( IC50) was 390 nmol·L- 1. Tacrolimus can markedly depress the migration of cells,the depression was more significant,when the concentration of tacrolimus was higher,and almost no cell was observed at the level of2 000 nmol · L- 1. Conclusions Tacrolimus can obviously inhibit hyperplasia of intimal thickness after venous transplantation,which may be related to the up-regulated expression of p27 and inhibition of smooth muscle cell proliferation and migration.
出处 《内科》 2016年第3期335-338,385,共5页 Internal Medicine
基金 广西自然科学基金(编号:2013GXNSFAA019151)
关键词 他克莫司 静脉桥 内膜增生 再狭窄 平滑肌细胞 Tacrolimus Vein graft Intimal hyperplasia Restenosis Smooth muscle cell
  • 相关文献

参考文献18

  • 1刘巍,周玉杰,刘宇扬,史东梅,吕树峥,陈方,李志忠.静脉桥病变的介入治疗及临床预后观察[J].心肺血管病杂志,2013,32(3):247-250. 被引量:11
  • 2Sur S, Sugimoto JT, Agrawal DK. Coronary artery bypass graft: why is the saphenous vein prone to intimal hypcrpla- sia? [ J ]. Can J Physiol Pharmacol, 2014,92 ( 7 ) : 531 - 545.
  • 3Raina A,Horn ET,Benza RL. The pathoph.vsiology of endo- thelin in complications after solid organ transplantation: a potential noveltherapeutic role for endothelin receptor antag- onists [ J ]. Transplantation, 2012,94 ( 9 ) : 885 - 893.
  • 4李婷,何宇,宋林淋,曹灵.环孢素A、他克莫司治疗特发性膜性肾病的研究进展[J].山东医药,2015,55(36):93-95. 被引量:13
  • 5吕小棉,陈亚丽.对抗经皮冠状动脉介入术后冠状动脉再狭窄的研究进展[J].心血管病学进展,2015,36(6):708-712. 被引量:7
  • 6Hamada N, Miyata M, Eto H, et al. Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signa- ling in porcine coronary artery model[ J]. Atherosclerosis, 2010,208 ( 1 ) :97 - 103.
  • 7Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP in- hibits cell cycle regulators of proliferation in vascular smooth muscle cells [ J ]. Circ Res, 1995,76 ( 3 ) : 412 - 417.
  • 8Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascu- lar smooth muscle cell migration[ J]. J Clin Invest, 1996, 98 (10) :2277 - 2283.
  • 9Wi JH,Joo HC, Youn YN,et al. Comparison of radial artery and saphenous vein composite Y grafts during off-pump cor- onary artery bypass [ J ]. Korean J Thorac Cardiovasc Surg, 2013, 46(4) :265 -273.
  • 10Shah P, Bajaj S, Virk H. Rapid progression of coronary ath- erosclerosis: A Review [ J ]. Thrombosis, 2015, 2015: 634983.

二级参考文献47

  • 1Veldkamp RF,Valk SD,Van Domburg RT,et al.Mortality andrepeat interventions up until 20 years after aorto-coronary bypasssurgery with saphenous vein grafts.A follow-up study of 1041 pa-tients.Eur Heart J,2000,21:747-753.
  • 2Brilakis ES,Rao SV,Banerjee S,et al.Percutaneous coronaryintervention in native arteries versus bypass grafts in prior coro-nary artery bypass grafting patients:a report from the NationalCardiovascular Data Registry.JACC Cardiovasc Interv,2011,4:844-850.
  • 3Hong YJ,Jeong MH,Ahn Y,et al.Impact of lesion location onintravascular ultrasound findings and short-term and five-yearlong-term clinical outcome after percutaneous coronary interven-tion for saphenous vein graft lesions.Int J Cardiol,2011,[Epubahead of print].
  • 4Parang P,Arora R.Coronary vein graft disease:pathogenesisand prevention.Can J Cardiol,2009,25:e57-62.
  • 5Silva JA,White CJ,Collins TJ,et al.Morphologic comparisonof atherosclerotic lesions in native coronary arteries and saphenousvein graphs with intracoronary angioscopy in patients with unsta-ble angina.Am Heart J,1998,136:156-163.
  • 6Kaplan S,Barlis P,Kiris A,et al.Immediate procedural andlong-term clinical outcomes following drug-eluting stent implanta-tion to ostial saphenous vein graft lesions.Acute Card Care,2008,10:88-92.
  • 7Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention.Areport of the American college of cardiology foundation/Americanheart association task force on practice guidelines and the societyfor cardiovascular angiography and interventions.J Am Coll Car-diol,2011,58:e44-122.
  • 8Swaminathan A,Stone GW,Rogers C,et al.Influence of vesseldiameter on the efficacy of distal protection devices during saphe-nous vein graft intervention.Am J Cardiol,2005,95:651-654.
  • 9Wiisanen ME,Abdel-Latif A,Mukherjee D,et al.Drug-elutingstents versus bare-metal stents in saphenous vein graft interven-tions:a systematic review and meta-analysis.JACC CardiovascInterv,2010,3:1262-1273.
  • 10Hakeem A,Helmy T,Munsif S,et al.Safety and efficacy ofdrug eluting stents compared with bare metal stents for saphenousvein graft interventions:a comprehensive meta-analysis of ran-domized trials and observational studies comprising 7,994 pa-tients.Catheter Cardiovasc Interv,2011,77:343-355.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部